Thrombotic thrombocytopenic purpura explained

Thrombotic thrombocytopenic purpura
Synonyms:Moschcowitz syndrome, idiopathic thrombotic thrombocytopenic purpura
Field:Hematology
Symptoms:Large bruises, fever, weakness, shortness of breath, confusion, headache
Onset:Adulthood
Causes:Unknown, bacterial infections, certain medications, autoimmune diseases, pregnancy
Diagnosis:Based on symptoms and blood tests
Differential:Hemolytic-uremic syndrome (HUS), atypical hemolytic uremic syndrome (aHUS)
Treatment:Plasma exchange, immunosuppressants
Prognosis:< 20% risk of death
Frequency:1 in 100,000 people

Thrombotic thrombocytopenic purpura (TTP) is a blood disorder that results in blood clots forming in small blood vessels throughout the body.[1] This results in a low platelet count, low red blood cells due to their breakdown, and often kidney, heart, and brain dysfunction. Symptoms may include large bruises, fever, weakness, shortness of breath, confusion, and headache.[1] [2] Repeated episodes may occur.[2]

In about half of cases a trigger is identified, while in the remainder the cause remains unknown.[2] Known triggers include bacterial infections, certain medications, autoimmune diseases such as lupus, and pregnancy.[2] The underlying mechanism typically involves antibodies inhibiting the enzyme ADAMTS13. This results in decreased break down of large multimers of von Willebrand factor (vWF) into smaller units. Less commonly TTP is inherited, known as Upshaw–Schulman syndrome, such that ADAMTS13 dysfunction is present from birth.[3] Diagnosis is typically based on symptoms and blood tests.[1] It may be supported by measuring activity of or antibodies against ADAMTS13.[1]

With plasma exchange the risk of death has decreased from more than 90% to less than 20%.[4] Immunosuppressants, such as glucocorticoids, and rituximab may also be used.[2] Platelet transfusions are generally not recommended.[5]

About 1 per 100,000 people are affected.[2] Onset is typically in adulthood and women are more often affected.[2] About 10% of cases begin in childhood.[2] The condition was first described by Eli Moschcowitz in 1924.[2] The underlying mechanism was determined in the 1980s and 1990s.[2]

Signs and symptoms

The signs and symptoms of TTP may at first be subtle and nonspecific. Many people experience an influenza-like or diarrheal illness before developing TTP.[6] Neurological symptoms are very common and vary greatly in severity. Frequently reported symptoms include feeling very tired, confusion, and headaches.[6] Seizures and symptoms similar to those of a stroke can also be seen.[6] Other symptoms include, but are not limited to jaundice or paleness of the skin, a fast heart rate or shortness of breath,[7] or dots on the skin known as petechiae.[8] High blood pressure has also been observed as a symptom.[9]

As TTP progresses, blood clots form within small blood vessels (microvasculature), and platelets (clotting cells) are consumed. As a result, bruising, and rarely bleeding can occur. The bruising often takes the form of purpura, while the most common site of bleeding, if it occurs, is from the nose or gums. Larger bruises (ecchymoses) may also develop.[10] The classic presentation of TTP, which occurs in less than 10% of people, includes five medical signs. These are:

Causes

TTP, as with other microangiopathic hemolytic anemias (MAHAs), is caused by spontaneous aggregation of platelets and activation of coagulation in the small blood vessels. Platelets are consumed in the aggregation process and bind vWF. These platelet-vWF complexes form small blood clots which circulate in the blood vessels and cause shearing of red blood cells, resulting in their rupture and formation of schistocytes.[11] The two best understood causes of TTP are due to autoimmunity (acquired TTP), caused by autoantibodies targeting ADAMTS13,[12] or congenital TTP: an inherited deficiency of ADAMTS13 (known as the Upshaw–Schulman syndrome).[11]

Autoimmune

In 1998, the majority of cases were shown to be caused by the inhibition of the enzyme ADAMTS13 by antibodies. Knowledge of this relationship between reduced ADAMTS13 and the pathogenesis of TTP is credited to two independent groups of researchers (Furlan and Tsai) who published their research in the same issue of the New England Journal of Medicine.[13]

ADAMTS13 is a metalloproteinase responsible for the breakdown of von Willebrand factor (vWF), a protein that links platelets, blood clots, and the blood vessel wall in the process of blood coagulation. Very large vWF multimers are more prone to lead to coagulation. Hence, without proper cleavage of vWF by ADAMTS13, coagulation occurs at a higher rate, especially in the microvasculature, part of the blood vessel system where vWF is most active due to high shear stress.[3]

Genetic

TTP may also be congenital. Such cases may be caused by mutations in the ADAMTS13 gene.[14] [15] This hereditary form of TTP is called the Upshaw–Schulman syndrome (also spelled Upshaw–Schülman).[16] [17] People with this inherited ADAMTS13 deficiency have a surprisingly mild phenotype, but develop TTP in clinical situations with increased von Willebrand factor levels, e.g. infection. Reportedly, less than 5% of all TTP cases are due to Upshaw–Schulman syndrome.[18] People with this syndrome generally have 5–10% of normal ADAMTS-13 activity.[19] [20]

Secondary

Secondary TTP is diagnosed when the person's history mentions one of the known features associated with TTP. It comprises about 40% of all cases of TTP. Predisposing factors are:[11]

The mechanism of secondary TTP is poorly understood, as ADAMTS13 activity is generally not as depressed as in idiopathic TTP, and inhibitors cannot be detected. Probable etiology may involve, at least in some cases, endothelial damage,[22] although the formation of thrombi resulting in vessel occlusion may not be essential in the pathogenesis of secondary TTP.[23] These factors may also be considered a form of secondary aHUS; people presenting with these features are, therefore, potential candidates for anticomplement therapy.

Pathophysiology

The underlying mechanism typically involves autoantibody-mediated inhibition of the enzyme ADAMTS13, a metalloprotease responsible for cleaving large multimers of von Willebrand factor (vWF) into smaller units. The increase in circulating multimers of vWF increases platelet adhesion to areas of endothelial injury, particularly where arterioles and capillaries meet, which in turn results in the formation of small platelet clots called thrombi.[24] As platelets are used up in the formation of thrombi, this then leads to a decrease in the number of overall circulating platelets, which may then cause life-threatening bleeds. Red blood cells passing the microscopic clots are subjected to shear stress, which damages their membranes, leading to rupture of red blood cells within blood vessels, which in turn leads to microangiopathic hemolytic anemia and schistocyte formation. The presence of the thrombi reduces blood flow to organs resulting in cellular injury and end organ damage.

Recovery

Depression is common in those recovering from TTP; 59% of recovered TTP patients screened positive for depression within 11 years after recovery.[25]

Diagnosis

Thrombotic thrombocytopenic purpura (TTP) initially presents with a range of symptoms that may include severe thrombocytopenia (platelet count usually < 30,000/mm³), microangiopathic hemolytic anemia (evidenced by schistocytes in the blood smear), and various clinical signs such as petechiae, purpura, neurologic symptoms, myocardial ischemia, mesenteric ischemia, and renal abnormalities. Notably, the complete classic pentad of TTP symptoms—microangiopathic hemolytic anemia, thrombocytopenia, renal abnormalities, fever, and neurologic abnormalities—is only seen in about 10% of acute cases at initial presentation.[26] Clinical suspicion of TTP is often established with an initial emergent presentation of one or more classic symptoms and a complete blood count revealing severe thrombocytopenia.[27]

The PLASMIC score[28], Bentley score,[29] and French TMA score[30] have been used to assess clinical probability of TTP.[31]

A definitive diagnosis of TTP may be established when a laboratory assay of ADAMTS13 identifies under 10% of normal enzyme function. Borderline or normal ADAMTS13 activity suggests a different diagnosis is more likely.

The ISTH guidelines suggested diagnostic and early management strategy.[32] Suggestions included 1) for high pretest probability based on PLASMIC score or French score, start TPE and corticosteroids, and collect plasma samples for ADAMTS13 testing before therapy. Consider caplacizumab if ADAMTS13 test results are expected within 72 hours. If ADAMTS13 <10 IU/dL, continue caplacizumab and rituximab. If ADAMTS13 is ≥20 IU/dL, consider to stop caplacizumab and seek other diagnoses. If ADAMTS13 activity is borderline, use clinical judgment; 2) for low or intermediate pretest probability, still consider TPE and corticosteroids, but withhold caplacizumab until plasma ADAMTS13 test results are available; if ADAMTS13 activity is <10 IU/dL, consider adding caplacizumab and rituximab; if ADAMTS13 activity is ≥20 IU/dL, no caplacizumab should be used and other diagnoses should be sought; if ADAMTS13 activity falls borderline, consider other diagnoses.

Differential diagnosis

TTP is a form of thrombotic microangiopathy (TMA),[33] the formation of blood clots in small blood vessels throughout the body, which can lead to microangiopathic hemolytic anemia and thrombocytopenia. This characteristic is shared by two related syndromes, hemolytic-uremic syndrome (HUS) and atypical hemolytic uremic syndrome (aHUS).[34] Consequently, differential diagnosis of these TMA diseases is essential. Both TTP and HUS are characterized by fever, anemia, thrombocytopenia, renal failure, and neurological symptoms. Generally, TTP has higher rates of neurological symptoms (≤80%) and lower rates of renal symptoms (9%) than HUS (10–20% and 90%, respectively).[35]

Unlike HUS and aHUS,[36] [37] TTP is known to be caused by a defect in the ADAMTS13 protein,[38] so a lab test showing ≤5% of normal ADAMTS13 levels is indicative of TTP. ADAMTS13 levels above 5%, coupled with a positive test for shiga-toxin/enterohemorrhagic E. coli (EHEC), are more likely indicative of HUS,[39] whereas absence of shiga-toxin/EHEC can confirm a diagnosis of aHUS.

Treatment

Due to the high mortality of untreated TTP, a presumptive diagnosis of TTP is made even when only microangiopathic hemolytic anemia and thrombocytopenia are seen, and therapy is started. Transfusion is contraindicated in thrombotic TTP, as it fuels the coagulopathy. Since the early 1990s, plasmapheresis has become the treatment of choice for TTP.[40] [41] This is an exchange transfusion involving removal of the person's blood plasma through apheresis and replacement with donor plasma (fresh frozen plasma or cryosupernatant); the procedure must be repeated daily to eliminate the inhibitor and abate the symptoms. If apheresis is not available, fresh frozen plasma can be infused, but the volume that can be given safely is limited due to the danger of fluid overload.[42] Plasma infusion alone is not as beneficial as plasma exchange.[40] Corticosteroids (prednisone or prednisolone) are usually given.[41] Rituximab, a monoclonal antibody aimed at the CD20 molecule on B lymphocytes, may be used on diagnosis; this is thought to kill the B cells and thereby reduce the production of the inhibitor.[41] A stronger recommendation for rituximab exists where TTP does not respond to corticosteroids and plasmapheresis.[41]

Caplacizumab is an adjunct option in treating TTP as it has been shown that it induces a faster disease resolution compared with those people who were on placebo.[43] However, the use of caplacizumab was associated with increase bleeding tendencies in some studied subjects.[44] Its cost-effectiveness has also been questioned.[45] Use of caplacizumab without plasmapheresis has been reported in select patients.[46] The MAYARI study was designed to evaluate the effectiveness of this option.[47]

The ISTH guidelines[48] recommended for first acute episode and relapses of immune-mediated TTP (iTTP), add corticosteroids to therapeutic plasma exchange (TPE) and consider adding rituximab and caplacizumab. For asymptomatic iTTP with low plasma ADAMTS13 activity, consider rituximab outside of pregnancy, but prophylactic TPE during pregnancy. For asymptomatic congenital TTP, offer prophylactic plasma infusion during pregnancy, and consider plasma infusion or a wait and watch approach outside of pregnancy.

People with refractory or relapsing TTP may receive additional immunosuppressive therapy, e.g. vincristine, cyclophosphamide, cyclosporine A, or splenectomy.[2]

Children with Upshaw-Schulman syndrome receive prophylactic plasma every two to three weeks; this maintains adequate levels of functioning ADAMTS13. Some tolerate longer intervals between plasma infusions. Additional plasma infusions may be necessary for triggering events, such as surgery; alternatively, the platelet count may be monitored closely around these events with plasma being administered if the count drops.[49]

Measurements of blood levels of lactate dehydrogenase, platelets, and schistocytes are used to monitor disease progression or remission.[50] ADAMTS13 activity and inhibitor levels may be measured during follow-up, but in those without symptoms the use of rituximab is not recommended.[41]

Apadamtase alfa (Adzynma) was approved for medical use in the United States in November 2023.[51] [52] The use of ADAMTS13 is well established for the treatment of congenital TTP.[53]

Prognosis

The mortality rate is around 95% for untreated cases, but the prognosis is reasonably favorable (80–90% survival) for people with idiopathic TTP diagnosed and treated early with plasmapheresis.[54]

Epidemiology

The incidence of TTP is about 4–5 cases per million people per year.[55] Idiopathic TTP occurs more often in women as well as people of African descent, and TTP secondary to autoimmune disorders such as systemic lupus erythematosus occurs more frequently in people of African descent, although other secondary forms do not show this distribution.[56] Although Black people are at an increased risk for TTP, its presentation in Black people does not have any distinguishable features compared to those of other races.[57] Pregnant women and women in the post partum period accounted for a notable portion (12–31%) of the cases in some studies; TTP affects about one in 25,000 pregnancies.[58]

History

TTP was initially described by Eli Moschcowitz at the Beth Israel Hospital in New York City in 1924.[59] Moschcowitz ascribed the disease (incorrectly, as now known) to a toxic cause. Moschcowitz noted his patient, a 16-year-old girl, had anemia, small and large bruises, microscopic hematuria, and, at autopsy, disseminated microvascular thrombi.[60] In 1966, a review of 16 new cases and 255 previously reported cases led to the formulation of the classical pentad of symptoms and findings (i.e., thrombocytopenia, microangiopathic hemolytic anemia, neurological symptoms, kidney failure, fever); in this series, mortality rates were found to be very high (90%).[61]

While a response to blood transfusion had been noted before, a 1978 report and subsequent studies showed blood plasma was highly effective in improving the disease process. In 1991, plasma exchange was reported to provide better response rates compared to plasma infusion.[62] In 1982, the disease had been linked with abnormally large von Willebrand factor multimers. The identification of a deficient protease in people with TTP was made in 1998. The location of ADAMTS13 within the human genome was identified in 2001.[63]

Notes and References

  1. Web site: Immune-mediated thrombotic thrombocytopenic purpura . . U.S. Department of Health & Human Services . 2018-10-10 . 2018-10-20 . https://web.archive.org/web/20181020052040/https://rarediseases.info.nih.gov/diseases/4607/thrombotic-thrombocytopenic-purpura-acquired . dead .
  2. Joly . Bérangère S. . Coppo . Paul . Veyradier . Agnès . vanc . May 2017 . Thrombotic thrombocytopenic purpura . Blood . 129 . 21 . 2836–2846 . 10.1182/blood-2016-10-709857 . 0006-4971 . 28416507. 2543348 . free .
  3. Moake . Joel L . vanc . January 2004 . Von Willebrand factor, ADAMTS-13, and thrombotic thrombocytopenic purpura . Seminars in Hematology . 41 . 1 . 4–14 . 10.1053/j.seminhematol.2003.10.003 . 0037-1963 . 14727254.
  4. Kremer Hovinga . Johanna A. . Coppo . Paul . Lämmle . Bernhard . Moake . Joel L. . Miyata . Toshiyuki . Vanhoorelbeke . Karen . vanc . April 2017 . Thrombotic thrombocytopenic purpura . Nature Reviews Disease Primers . en . 3 . 17020 . 10.1038/nrdp.2017.20 . 2056-676X . 28382967 . 11960153 . 17020.
  5. Book: Wood . Marie E. . Hematology/Oncology Secrets . Philips . George K. . Elsevier . 2003 . 978-1-56053-516-4 . 3rd . 68.
  6. Shatzel . Joseph J. . Taylor . Jason A. . vanc . March 2017 . Syndromes of Thrombotic Microangiopathy . Medical Clinics of North America . 101 . 2 . 395–415 . 10.1016/j.mcna.2016.09.010 . 0025-7125 . 28189178 . 24123004.
  7. Web site: Thrombotic thrombocytopenic purpura . MedlinePlus Genetics . . en.
  8. Web site: Updated March 24, 2022 . Platelet Disorders - Thrombotic Thrombocytopenic Purpura (TTP) . . 24 March 2022 . en.
  9. Shibagaki . Yugo . Fujita . Toshiro . vanc . January 2005 . Thrombotic Microangiopathy in Malignant Hypertension and Hemolytic Uremic Syndrome (HUS)/Thrombotic Thrombocytopenic Purpura (TTP): Can We Differentiate One from the Other? . Hypertension Research . en . 28 . 1 . 89–95 . 10.1291/hypres.28.89 . 15969259 . 139098502 . 1348-4214. free .
  10. Chiasakul . Thita . Cuker . Adam . vanc . November 2018 . Clinical and laboratory diagnosis of TTP: an integrated approach . Hematology . 2018 . 1 . 530–538 . 10.1182/asheducation-2018.1.530 . 1520-4391 . 6246034 . 30504354 . 54564230.
  11. Moake . Joel L. . vanc . August 2022 . Thrombotic Microangiopathies . New England Journal of Medicine . en . 347 . 8 . 589–600 . 10.1056/NEJMra020528 . 0028-4793 . 12192020 . 40055198.
  12. Book: Stanley . Michael . StatPearls . Killeen . Robert B. . Michalski . Joel M. . January 2023 . StatPearls Publishing . Thrombotic Thrombocytopenic Purpura . 28613472 . https://www.ncbi.nlm.nih.gov/books/NBK430721/ . vanc.
  13. Moake . Joel L. . vanc . November 1998 . Moschcowitz, Multimers, and Metalloprotease . New England Journal of Medicine . en . 339 . 22 . 1629–1631 . 10.1056/NEJM199811263392210 . 0028-4793 . 9828253.
  14. Conboy . Erin . Partain . Paige I. . Warad . Deepti . Kluge . Michelle L. . Arndt . Carola . Chen . Dong . Rodriguez . Vilmarie . vanc . January 2018 . A Severe Case of Congenital Thrombotic Thrombocytopenia Purpura Resulting From Compound Heterozygosity Involving a Novel ADAMTS13 Pathogenic Variant . Journal of Pediatric Hematology/Oncology . en-US . 40 . 1 . 60–62 . 10.1097/MPH.0000000000000895 . 1077-4114 . 28678087 . 3470460.
  15. Lämmle . Bernhard . Hovinga . Johanna A. Kremer . George . James N. . vanc . February 2008 . Acquired thrombotic thrombocytopenic purpura: ADAMTS13 activity, anti-ADAMTS13 autoantibodies and risk of recurrent disease . Haematologica . en . 93 . 2 . 172–177 . 10.3324/haematol.12701 . 1592-8721 . 18245649. 17777111 . free .
  16. Kremer Hovinga . Johanna A. . George . James N. . vanc . October 2019 . Longo . Dan L. . Hereditary Thrombotic Thrombocytopenic Purpura . New England Journal of Medicine . en . 381 . 17 . 1653–1662 . 10.1056/NEJMra1813013 . 31644845 . 204864996 . 0028-4793.
  17. Chapman . Kent . Seldon . Michael . Richards . Ross . vanc . February 2012 . Thrombotic Microangiopathies, Thrombotic Thrombocytopenic Purpura, and ADAMTS-13 . Seminars in Thrombosis and Hemostasis . en . 38 . 1 . 47–54 . 10.1055/s-0031-1300951 . 0094-6176 . 22314603. 13963783 . free .
  18. Book: Tsai, Han-Mou . Wintrobe's Clinical Hematology . Wolters Kluwer . 2023 . 978-1-975184-69-8 . Means . Robert T. Jr. . 15th . 2 . Thrombotic Thrombocytopenic Purpura, Hemolytic-Uremic Syndrome, and Related Disorders . Arber . Daniel A. . Glader . Bertil E. . Appelbaum . Frederick R. . Rodgers . George M. . Dispenzieri . Angela . Fehniger . Todd A. . Michaelis . Laura C. . Leonard . John P. . vanc.
  19. Levy . Gallia G. . Nichols . William C. . Lian . Eric C. . Foroud . Tatiana . McClintick . Jeanette N. . McGee . Beth M. . Yang . Angela Y. . Siemieniak . David R. . Stark . Kenneth R. . Gruppo . Ralph . Sarode . Ravindra . Shurin . Susan B. . Chandrasekaran . Visalam . Stabler . Sally P. . Sabio . Hernan . vanc . October 2001 . Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura . Nature . en . 413 . 6855 . 488–494 . 2001Natur.413..488L . 10.1038/35097008 . 1476-4687 . 11586351 . 4380010 . free . 2027.42/62592.
  20. Kokame . Koichi . Matsumoto . Masanori . Soejima . Kenji . Yagi . Hideo . Ishizashi . Hiromichi . Funato . Masahisa . Tamai . Hiroshi . Konno . Mutsuko . Kamide . Kei . Kawano . Yuhei . Miyata . Toshiyuki . Fujimura . Yoshihiro . vanc . September 2002 . Mutations and common polymorphisms in ADAMTS13 gene responsible for von Willebrand factor-cleaving protease activity . Proceedings of the National Academy of Sciences . en . 99 . 18 . 11902–11907 . 2002PNAS...9911902K . 10.1073/pnas.172277399 . 0027-8424 . 129366 . 12181489 . 20496927 . free .
  21. Book: Menkes. John H.. Harvey B. . Sarnat. Bernard L. . Maria. Thrombotic Thrombocytopenic Purpura and Hemolytic-Uremic Syndrome. Child Neurology. 7th . Philadelphia. Lippincott Williams & Wilkins. 2006 . 525 . 9780781751049.
  22. van Mourik . Jan A. . Boertjes . Ria . Huisveld . Inge A. . Fijnvandraat . Karin . Pajkrt . Dasja . van Genderen . Perry J.J. . Fijnheer . Rob . vanc . 1999-07-01 . von Willebrand Factor Propeptide in Vascular Disorders: A Tool to Distinguish Between Acute and Chronic Endothelial Cell Perturbation . Blood . en . 94 . 1 . 179–185 . 10.1182/blood.V94.1.179.413k18_179_185 . 1528-0020 . 10381511.
  23. Iwata H, Kami M, Hori A, Hamaki T, Takeuchi K, Mutou Y . An autopsy-based retrospective study of secondary thrombotic thrombocytopenic purpura . . 86 . 6 . 669–70 . June 2001 . 11418383 .
  24. Tsai . Han-Mou . vanc . January 2010 . Pathophysiology of thrombotic thrombocytopenic purpura . International Journal of Hematology . en . 91 . 1 . 1–19 . 10.1007/s12185-009-0476-1 . 1865-3774 . 3159000 . 20058209.
  25. Han . Bowie . Page . Evaren E. . Stewart . Lauren M. . Deford . Cassandra C. . Scott . James G. . Schwartz . Lauren H. . Perdue . Jedidiah J. . Terrell . Deirdra R. . Vesely . Sara K. . George . James N. . vanc . August 2018 . Depression and cognitive impairment following recovery from thrombotic thrombocytopenic purpura: Depression and Cognitive Impairment Following TTP . American Journal of Hematology . en . 90 . 8 . 709–714 . 10.1002/ajh.24060 . 4509840 . 25975932.
  26. Book: Hardin, J. Matthew . The atlas of emergency medicine . 2021 . McGraw-Hill Education . 978-1-260-13495-7 . Knoop . Kevin J. . 5th . New York . 13-07: Thrombotic Thrombocytopenic Purpura . Stack . Lawrence B. . Storrow . Alan B. . Thurman . R. Jason.
  27. Book: Konkle, Barbara . Harrison's principles of internal medicine . 2022 . McGraw Hill . 978-1-264-26851-1 . Loscalzo . Joseph . 21st . New York . Chapter 115: Disorders of Platelets and Vessel Wall . Fauci . Anthony S. . Kasper . Dennis L. . Hauser . Stephen L. . Longo . Dan L. . Jameson . J. Larry.
  28. Bendapudi PK, Hurwitz S, Fry A, Marques MB, Waldo SW, Li A, Sun L, Upadhyay V, Hamdan A, Brunner AM, Gansner JM, Viswanathan S, Kaufman RM, Uhl L, Stowell CP, Dzik WH, Makar RS. Derivation and external validation of the PLASMIC score for rapid assessment of adults with thrombotic microangiopathies: a cohort study. Lancet Haematol. 2017 Apr;4(4):e157-e164. doi: 10.1016/S2352-3026(17)30026-1. Epub 2017 Mar 2. PMID: 28259520.
  29. Bentley MJ, Lehman CM, Blaylock RC, Wilson AR, Rodgers GM. The utility of patient characteristics in predicting severe ADAMTS13 deficiency and response to plasma exchange. Transfusion. 2010 Aug;50(8):1654-64. doi: 10.1111/j.1537-2995.2010.02653.x. Epub 2010 Apr 20. PMID: 20412532.
  30. Coppo P, Schwarzinger M, Buffet M, Wynckel A, Clabault K, Presne C, Poullin P, Malot S, Vanhille P, Azoulay E, Galicier L, Lemiale V, Mira JP, Ridel C, Rondeau E, Pourrat J, Girault S, Bordessoule D, Saheb S, Ramakers M, Hamidou M, Vernant JP, Guidet B, Wolf M, Veyradier A; French Reference Center for Thrombotic Microangiopathies. Predictive features of severe acquired ADAMTS13 deficiency in idiopathic thrombotic microangiopathies: the French TMA reference center experience. PLoS One. 2010 Apr 23;5(4):e10208. doi: 10.1371/journal.pone.0010208. PMID: 20436664; PMCID: PMC2859048.
  31. Park SH, Kim HK, Jeong J, Lee SH, Lee YJ, Kim YJ, Jo JC, Lim JH. Performance Validation of Three Scoring Systems for the Prediction of Thrombotic Microangiopathy Due to Severe ADAMTS13 Deficiency and the Response to Therapeutic Plasma Exchange: First Study in Korea. Ann Lab Med. 2023 Sep 1;43(5):485-492. doi: 10.3343/alm.2023.43.5.485. Epub 2023 Apr 21. PMID: 37080750; PMCID: PMC10151285.
  32. Zheng XL, Vesely SK, Cataland SR, Coppo P, Geldziler B, Iorio A, Matsumoto M, Mustafa RA, Pai M, Rock G, Russell L, Tarawneh R, Valdes J, Peyvandi F. ISTH guidelines for the diagnosis of thrombotic thrombocytopenic purpura. J Thromb Haemost. 2020 Oct;18(10):2486-2495. doi: 10.1111/jth.15006. Epub 2020 Sep 11. Erratum in: J Thromb Haemost. 2021 May;19(5):1381. doi: 10.1111/jth.15304. PMID: 32914582; PMCID: PMC8146131.
  33. Arnold . Donald M. . Patriquin . Christopher J. . Nazy . Ishac . vanc . January 2017 . Thrombotic microangiopathies: a general approach to diagnosis and management . CMAJ . en . 189 . 4 . E153–E159 . 10.1503/cmaj.160142 . 0820-3946 . 5266569 . 27754896.
  34. George . James N. . vanc . November 2010 . How I treat patients with thrombotic thrombocytopenic purpura: 2010 . Blood . en . 116 . 20 . 4060–4069 . 10.1182/blood-2010-07-271445 . 0006-4971 . 20686117 . 26844964. free .
  35. Web site: 2023-04-26 . MAHA, TTP, HUS, DIC... Oh My! Understanding Microangiopathic Hemolytic Anemias . 2023-08-23 . Tampa Emergency Medicine Blog . . en-US.
  36. Book: Abrams, Charles S. . Goldman's Cecil Medicine . Elsevier . 2012 . 978-1437716047 . Goldman . Lee . 24th . 1 . Thrombocytopenia . 1124–1131 . 10.1016/B978-1-4377-1604-7.00175-5 . In contrast to TTP, HUS is not caused by a deficiency of ADAMTS13. . Schafer . Andrew I. . https://www.sciencedirect.com/science/article/abs/pii/B9781437716047001755 . vanc.
  37. Feng . Shuju . Eyler . Stephen J. . Zhang . Yuzhou . Maga . Tara . Nester . Carla M. . Kroll . Michael H. . Smith . Richard J. . Afshar-Kharghan . Vahid . vanc . August 2013 . Partial ADAMTS13 deficiency in atypical hemolytic uremic syndrome . Blood . 122 . 8 . 1487–1493 . 10.1182/blood-2013-03-492421 . 1528-0020 . 3750341 . 23847193 . Complement dysregulation leads to atypical hemolytic uremic syndrome (aHUS), while ADAMTS13 deficiency causes thrombotic thrombocytopenic purpura..
  38. Cataland . Spero R. . Wu . Haifeng M. . April 2014 . How I treat: the clinical differentiation and initial treatment of adult patients with atypical hemolytic uremic syndrome . Blood . en . 123 . 16 . 2478–2484 . 10.1182/blood-2013-11-516237 . 24599547 . 0006-4971. free .
  39. Bitzan . Martin . Schaefer . Franz . Reymond . Didier . vanc . September 2010 . Treatment of typical (enteropathic) hemolytic uremic syndrome . Seminars in Thrombosis and Hemostasis . 36 . 6 . 594–610 . 10.1055/s-0030-1262881 . 1098-9064 . 20865636 . 6129618.
  40. Michael . M . Elliott . EJ . Ridley . GF . Hodson . EM . Craig . JC . January 2009 . Interventions for haemolytic uraemic syndrome and thrombotic thrombocytopenic purpura. . The Cochrane Database of Systematic Reviews . 1 . 1 . CD003595–CD003595–63 . 10.1002/14651858.CD003595.pub2 . 7154575 . 19160220 . 10072/61440.
  41. Lim W, Vesely SK, George JN . March 2015 . The role of rituximab in the management of patients with acquired thrombotic thrombocytopenic purpura . Blood . 125 . 10 . 1526–31 . 10.1182/blood-2014-10-559211 . 4351502 . 25573992.
  42. Allford SL, Hunt BJ, Rose P, Machin SJ . 38774829 . Guidelines on the diagnosis and management of the thrombotic microangiopathic haemolytic anaemias . British Journal of Haematology . 120 . 4 . 556–73 . February 2003 . 12588343 . 10.1046/j.1365-2141.2003.04049.x . free .
  43. Peyvandi . Flora . Scully . Marie . Kremer Hovinga . Johanna A. . Cataland . Spero . Knöbl . Paul . Wu . Haifeng . Artoni . Andrea . Westwood . John-Paul . Mansouri Taleghani . Magnus . vanc . February 2016 . Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura . New England Journal of Medicine . 374 . 6 . 511–522 . 10.1056/NEJMoa1505533 . 0028-4793 . 26863353 . 19482364 . free . 2434/829303. free .
  44. Goshua . George . Bendapudi . Pavan K. . vanc . December 2022 . Evidence-Based Minireview: Should caplacizumab be used routinely in unselected patients with immune thrombotic thrombocytopenic purpura? . Hematology . 2022 . 1 . 491–494 . 10.1182/hematology.2022000412 . 1520-4391 . 9820987 . 36485149.
  45. Goshua G, Sinha P, Hendrickson JE, Tormey C, Bendapudi PK, Lee AI. Cost effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura. Blood. 2021 Feb 18;137(7):969-976. doi: 10.1182/blood.2020006052. PMID: 33280030; PMCID: PMC7918179.
  46. Völker LA, Brinkkoetter PT, Knöbl PN, Krstic M, Kaufeld J, Menne J, Buxhofer-Ausch V, Miesbach W. Treatment of acquired thrombotic thrombocytopenic purpura without plasma exchange in selected patients under caplacizumab. J Thromb Haemost. 2020 Nov;18(11):3061-3066. doi: 10.1111/jth.15045. Epub 2020 Sep 6. PMID: 32757435; PMCID: PMC7692904.
  47. Web site: NCT05468320 . Caplacizumab and Immunosuppressive Therapy Without Firstline Therapeutic Plasma Exchange in Adults With Immune-mediated Thrombotic Thrombocytopenic Purpura (MAYARI) . Clinicaltrials.gov . NCI . August 4, 2024.
  48. Zheng XL, Vesely SK, Cataland SR, Coppo P, Geldziler B, Iorio A, Matsumoto M, Mustafa RA, Pai M, Rock G, Russell L, Tarawneh R, Valdes J, Peyvandi F. ISTH guidelines for treatment of thrombotic thrombocytopenic purpura. J Thromb Haemost. 2020 Oct;18(10):2496-2502. doi: 10.1111/jth.15010. Epub 2020 Sep 11. PMID: 32914526; PMCID: PMC8091490.
  49. Loirat . Chantal . Girma . Jean-Pierre . Desconclois . Céline . Coppo . Paul . Veyradier . Agnès . vanc . January 2009 . Thrombotic thrombocytopenic purpura related to severe ADAMTS13 deficiency in children . Pediatric Nephrology . en . 24 . 1 . 19–29 . 10.1007/s00467-008-0863-5 . 1432-198X . 18574602 . 22209831.
  50. Saha . M. . McDaniel . J.K. . Zheng . X.L. . vanc . October 2010 . Thrombotic thrombocytopenic purpura: pathogenesis, diagnosis and potential novel therapeutics . Journal of Thrombosis and Haemostasis . 15 . 10 . 1889–1900 . 10.1111/jth.13764 . 1538-7836 . 5630501 . 28662310 . 40493167.
  51. FDA Approves First Treatment for Patients with Rare Inherited Blood Clotting Disorder . U.S. Food and Drug Administration . 9 November 2023 . 30 November 2023.
  52. Takeda's Adzynma (ADAMTS13, recombinant-krhn) Approved by U.S. FDA as the First and Only Recombinant ADAMTS13 Enzyme Replacement Therapy for the Treatment of Congenital Thrombotic Thrombocytopenic Purpura (cTTP) . Takeda Pharmaceuticals . Business Wire . 9 November 2023 . 30 November 2023.
  53. Scully M, Antun A, Cataland SR, Coppo P, Dossier C, Biebuyck N, Hassenpflug WA, Kentouche K, Knöbl P, Kremer Hovinga JA, López-Fernández MF, Matsumoto M, Ortel TL, Windyga J, Bhattacharya I, Cronin M, Li H, Mellgård B, Patel M, Patwari P, Xiao S, Zhang P, Wang LT; cTTP Phase 3 Study Investigators. Recombinant ADAMTS13 in Congenital Thrombotic Thrombocytopenic Purpura. N Engl J Med. 2024 May 2;390(17):1584-1596. doi: 10.1056/NEJMoa2314793. PMID: 38692292.
  54. Tsai . Han-Mou . vanc . February 2006 . Current Concepts in Thrombotic Thrombocytopenic Purpura . Annual Review of Medicine . 57 . 419–436 . 10.1146/annurev.med.57.061804.084505 . 2426955 . 16409158.
  55. Terrell DR, Williams LA, Vesely SK, Lämmle B, Hovinga JA, George JN . July 2005 . The incidence of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: all patients, idiopathic patients, and patients with severe ADAMTS-13 deficiency . Journal of Thrombosis and Haemostasis . 3 . 7 . 1432–6 . 10.1111/j.1538-7836.2005.01436.x . 15978100 . 24914279. free .
  56. Terrell DR, Vesely SK, Kremer Hovinga JA, Lämmle B, George JN . November 2010 . Different disparities of gender and race among the thrombotic thrombocytopenic purpura and hemolytic-uremic syndromes . American Journal of Hematology . 85 . 11 . 844–7 . 10.1002/ajh.21833 . 3420337 . 20799358 . 23118040.
  57. Martino . Suella . Jamme . Mathieu . Deligny . Christophe . Busson . Marc . Loiseau . Pascale . Azoulay . Elie . Galicier . Lionel . Pène . Frédéric . Provôt . François . Dossier . Antoine . Saheb . Samir . Veyradier . Agnès . Coppo . Paul . Microangiopathies . French Reference Center for Thrombotic . 2016-07-06 . Thrombotic Thrombocytopenic Purpura in Black People: Impact of Ethnicity on Survival and Genetic Risk Factors . PLOS ONE . en . 11 . 7 . e0156679 . 10.1371/journal.pone.0156679 . 1932-6203 . 4934773 . 27383202 . 2016PLoSO..1156679M . free .
  58. Zheng . X. Long . Sadler . J. Evan . J. Evan Sadler . vanc . 2008 . Pathogenesis of Thrombotic Microangiopathies . Annual Review of Pathology . 3 . 249–277 . 10.1146/annurev.pathmechdis.3.121806.154311 . 2582586 . 18215115.
  59. Sukumar . Senthil . Lämmle . Bernhard . Cataland . Spero R. . vanc . January 2021 . Thrombotic Thrombocytopenic Purpura: Pathophysiology, Diagnosis, and Management . Journal of Clinical Medicine . en . 10 . 3 . 536 . 10.3390/jcm10030536 . 2077-0383 . 7867179 . 33540569 . free .
  60. Moschcowitz . Eli . vanc . 1924 . Hyaline Thrombosis of the Terminal Arterioles and Capillaries: A Hitherto Undescribed Disease . Proceedings of the New York Pathological Society . 24 . 21–24.
  61. Amorosi . Edward L. . Ultmann . John E. . vanc . March 1966 . Thrombotic thrombocytopenic purpura: report of 16 cases and review of the literature . Medicine . en-US . 45 . 2 . 139 . 10.1097/00005792-196603000-00003 . 71943329. free .
  62. 10.1056/NEJM199108083250604 . Rock GA . Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group . New England Journal of Medicine . 325 . 6 . 393–7 . August 1991 . 2062330 . vanc. Shumak KH . Buskard NA . 3 . Blanchette . Victor S. . Kelton . John G. . Nair . Rama C. . Spasoff . Robert A.. free .
  63. Sadler. JE. Von Willerbrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura. Blood. 2008. 112. 1. 11–18. 10.1182/blood-2008-02-078170. 18574040. 2435681.

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Thrombotic thrombocytopenic purpura".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.